WO2022158893A2 - 점안 조성물 - Google Patents
점안 조성물 Download PDFInfo
- Publication number
- WO2022158893A2 WO2022158893A2 PCT/KR2022/001095 KR2022001095W WO2022158893A2 WO 2022158893 A2 WO2022158893 A2 WO 2022158893A2 KR 2022001095 W KR2022001095 W KR 2022001095W WO 2022158893 A2 WO2022158893 A2 WO 2022158893A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- eye drop
- present
- bromfenac
- hydrate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 136
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims description 37
- 229960003655 bromfenac Drugs 0.000 claims description 37
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 32
- 239000003889 eye drop Substances 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 30
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 22
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 21
- 229940069328 povidone Drugs 0.000 claims description 20
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 239000003755 preservative agent Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 239000003002 pH adjusting agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 4
- BIYQNLJPABKADF-UHFFFAOYSA-M sodium;2-[2-amino-3-(4-bromobenzoyl)phenyl]acetate;hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 BIYQNLJPABKADF-UHFFFAOYSA-M 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012929 tonicity agent Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- -1 inorganic acid salts Chemical class 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- 206010039705 Scleritis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- DLNMWZQESQRFLV-UHFFFAOYSA-N 2-[2-amino-3-(4-bromobenzoyl)phenyl]-2-oxoacetic acid Chemical compound NC1=C(C(=O)C(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 DLNMWZQESQRFLV-UHFFFAOYSA-N 0.000 description 2
- JDSPXIPYMUGSIJ-UHFFFAOYSA-N 7-(4-bromobenzoyl)-1,3-dihydroindol-2-one Chemical compound C1=CC(Br)=CC=C1C(=O)C1=CC=CC2=C1NC(=O)C2 JDSPXIPYMUGSIJ-UHFFFAOYSA-N 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000005430 oxychloro group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to an ophthalmic composition comprising bromfenac, and more particularly, to an ophthalmic composition comprising bromfenac, povidone and hydroxypropylbetadex.
- Inflammatory eye diseases such as conjunctivitis, valvular adenitis, keratitis, blepharitis, and scleritis are frequent eye diseases.
- Bromfenac is a representative non-steroidal anti-inflammatory agent, and has an anti-inflammatory and analgesic effect, and thus is usefully used in the treatment of such inflammatory eye diseases.
- bromfenac is prepared in an aqueous formulation, a problem of stability may occur.
- the present invention relates to bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof; povidone; And it provides an ophthalmic composition comprising hydroxypropyl betadex.
- the present inventors have found that bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof; povidone; And the present invention was completed by confirming that the eye drop composition comprising hydroxypropyl betadex maintains properties during storage and exhibits excellent stability by minimizing the generation of related substances.
- the present invention relates to bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof; povidone; And it provides an ophthalmic composition comprising hydroxypropyl betadex.
- the eye drop composition of the present invention does not cause insoluble precipitation and color change during storage, the content is well maintained, and the amount of related substances is small, so it has excellent properties and storage stability. Economical.
- the ophthalmic composition of the present invention has excellent ocular feeling, so that there is little or no foreign body feeling and bitterness during instillation, and it is harmless to the human body and thus can be usefully used as an ophthalmic composition.
- bromfenac (Bromfenac) refers to a compound of the following formula, and is a type of acetic acid-based nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase activity It exhibits analgesic and anti-inflammatory effects.
- NSAID nonsteroidal anti-inflammatory drug
- the "pharmaceutically acceptable salt” refers to a salt commonly used in the pharmaceutical industry, and includes, for example, inorganic ionic salts such as sodium, inorganic acid salts such as hydrochloric acid, and organic acid salts.
- the pharmaceutically acceptable salt may be a sodium salt, but is not limited thereto.
- the "hydrate” refers to a combination of bromfenac or a pharmaceutically acceptable salt thereof and water by a non-covalent intermolecular force, and may include a stoichiometric or non-stoichiometric amount of water. have.
- the "solvate” refers to a combination of bromfenac or a pharmaceutically acceptable salt thereof and a solvent other than water by a non-covalent intermolecular force, and the solvent is added in a stoichiometric or non-stoichiometric amount.
- bromfenac may refer not only to the compound represented by the above formula, but also to a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof.
- composition of the present invention includes bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof as an active ingredient, and may specifically include bromfenac sodium hydrate, but is not limited thereto. not.
- the bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof may be contained in a therapeutically effective amount to achieve the purpose for analgesic and/or anti-inflammatory use, specifically It may be included in an amount of about 0.01 w/v% to about 0.5 w/v% based on the total ophthalmic composition, and more specifically, about 0.05 w/v% to about 0.5 w/v%, about 0.1 w/v% to about 0.3 w/v% or from about 0.05 w/v% to about 0.3 w/v%, more specifically from about 0.1 w/v% to about 0.2 w/v%, from about 0.15 w/v% to about 0.2 w It may be included in a content of /v%, but is not limited thereto.
- the bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof is about 0.01 w/v% or more, about 0.05 w/v% or more, about 0.1 w/v% or more, based on the total ophthalmic composition. or more, it may be included in an amount of about 0.15 w/v% or more, about 0.2 w/v% or more, and about 0.5 w/v% or less, about 0.3 w/v% or less, about 0.2 w/v% or less
- the present invention is not limited thereto.
- composition of the present invention may be used for analgesic and/or anti-inflammatory purposes, and may be used for analgesic and/or anti-inflammatory effects due to the nature of the composition comprising bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof.
- Blepharitis, conjunctivitis, scleritis including episcleritis, and inflammatory diseases of the outer and anterior segments of the eye, such as post-operative inflammation, or any symptoms related thereto, can be effectively used for prevention or treatment.
- composition of the present invention includes povidone (Povidone, Polyvinyl pyrrolidone; PVP).
- the povidone may be included in an amount of about 0.1 w/v% to about 10 w/v% based on the total ophthalmic composition, specifically, about 0.5 w/v% to about 10 w/v% or about 0.5 w/v% to about 0.5 w/v% to In an amount of about 5 w/v%, more specifically, it may be included in an amount of about 1 w/v% to about 4 w/v% or about 2 w/v%, but is not limited thereto.
- the povidone may be included in an amount of about 0.1 w/v% or more, about 0.5 w/v% or more, about 1 w/v% or more, based on the total eye drop composition, about 10 w/v% or less, about 5 w/v% Hereinafter, it may be included in an amount of about 4 w/v% or less, but is not limited thereto.
- composition of the present invention comprises hydroxypropyl betadex (Hydroxypropylbetadex). Hydroxypropyl betadex is also called hydroxypropyl- ⁇ -cyclodextrin (HP- ⁇ -CD).
- the hydroxypropyl betadex may be included in an amount of about 0.05 w/v% to about 20 w/v% based on the total ophthalmic composition, specifically, about 0.1 w/v% to about 20 w/v% or about 0.1 w /v% to about 10 w/v%, more specifically about 0.5 w/v% to about 5 w/v%, about 1 w/v% to about 5 w/v% or about 2 w/v% %, but is not limited thereto.
- the hydroxypropyl betadex may be included in an amount of about 0.05 w/v% or more, about 0.1 w/v% or more, about 0.5 w/v% or more, based on the total ophthalmic composition, and about 20 w/v% or less, about 10 It may be included in an amount of w/v% or less, about 5 w/v% or less, but is not limited thereto. It is preferable in terms of stability of the composition of the present invention that the hydroxypropyl betadex is included in an amount of about 0.1 w/v% or more based on the total ophthalmic composition.
- composition of the present invention maintains properties and content during storage and exhibits excellent stability by minimizing the amount of related substances.
- composition of the present invention contains bromfenac, povidone and hydroxypropyl betadex and has excellent properties, content and storage stability.
- composition of the present invention exhibits excellent stability by maintaining the properties without changing during storage, and also It was confirmed that the content was well maintained during storage and the amount of related substances was small, indicating excellent stability.
- composition of the present invention may further comprise an additive.
- composition of the present invention may further include one or more additives selected from a pH adjusting agent, a buffering agent, a tonicity agent, a viscosity adjusting agent, a solubilizing agent, a stabilizer, and a preservative.
- additives selected from a pH adjusting agent, a buffering agent, a tonicity agent, a viscosity adjusting agent, a solubilizing agent, a stabilizer, and a preservative.
- pH adjusting agent sodium hydroxide, hydrochloric acid, etc. may be used, and in order to obtain an appropriate pH, a required amount may be added by a method known to those skilled in the art.
- the pH of the composition of the present invention may be from about 5 to about 9, specifically, from about 6 to about 9, but is not limited thereto.
- acetic acid and/or a salt thereof citric acid and/or a salt thereof, phosphoric acid and/or a salt thereof, boric acid and/or a salt thereof, borax, and the like may be used, but is not limited thereto.
- the buffer may be included in an amount of about 0.1 w/v% to about 20 w/v% based on the total ophthalmic composition, but is not limited thereto.
- the isotonic agent glycerol, mannitol, sorbitol, sodium chloride, potassium chloride, boric acid, and the like may be used.
- the isotonic agent may be included in an amount of about 1 w/v% to about 20 w/v% based on the total ophthalmic composition, but is not limited thereto.
- the viscosity modifier includes: a cellulose-based compound including carboxymethyl cellulose; polyvinyl-based compounds including polyvinyl alcohol (PVA) and the like; acrylic compounds including carbomer and the like; gum compounds including Xanthan Gum and the like; Polysaccharides including sodium hyaluronate (Sodium Hyaluronate), sodium alginate (Sodium Alginate), or any combination thereof, etc. may be used, and in order to obtain an appropriate viscosity, a required amount may be added by a method known to those skilled in the art. .
- the viscosity modifier may be included in an amount of about 0.05 w/v% to about 10.0 w/v% based on the total ophthalmic composition, but is not limited thereto.
- solubilizing agent polyoxyethylene (hydrogenated) castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, a copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol polyalkylaryl ether, etc. may be used. .
- the solubilizing agent may be included in an amount of about 0.05 w/v% to about 5.0 w/v% based on the total ophthalmic composition, but is not limited thereto.
- sodium edetate sodium sulfite, and the like may be used.
- the stabilizer may be included in an amount of about 0.01 w/v% to about 1.0 w/v% based on the total ophthalmic composition, but is not limited thereto.
- the preservatives include quaternary ammonium compounds including benzalkonium chloride, polyquaternium-1, and the like; guanidine-based compounds including polyhexamethylenebiguanide and chlorhexidine; chlorobutanol; mercury preservatives including thimerosal and the like; and oxidative preservatives including stabilized oxychloro complexes, alkyl para-hydroxy acids, and the like.
- the preservative may be included in an amount of about 0.001 w/v% to about 0.02 w/v% based on the total ophthalmic composition, but is not limited thereto.
- composition of the present invention is specially formulated for topical application, and may be administered topically by formulations such as solutions, emulsions, suspensions, gels, or ointments.
- the present invention provides a composition according to (1) to (8):
- bromfenac a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof; povidone; And an eye drop composition comprising hydroxypropyl betadex (Hydroxypropylbetadex).
- (6) at least one additive selected from among (1), (2), (3), (4) or (5) above, a pH adjuster, a buffer, an isotonic agent, a viscosity adjuster, a solubilizer, a stabilizer, and a preservative
- An eye drop composition further comprising a.
- the present invention relates to bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof; povidone; And it may provide a method for preparing an eye drop composition comprising the step of mixing hydroxypropyl betadex.
- the present invention relates to bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof; povidone; And it may provide a method of stabilizing bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof, comprising the step of mixing hydroxypropylbetadex.
- the present invention provides an anti-inflammatory method comprising administering the above-described eye drop composition to a subject.
- the present invention provides bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof; povidone; And it provides an anti-inflammatory method comprising administering to the subject an eye drop composition comprising hydroxypropyl betadex.
- the present invention also provides an anti-inflammatory use of the above-mentioned eye drop composition.
- the present invention provides bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof; povidone; And it provides an anti-inflammatory use of the eye drop composition comprising hydroxypropyl betadex.
- the present invention also provides the use of the above-mentioned eye drop composition for the manufacture of an anti-inflammatory medicament.
- the present invention provides bromfenac, a pharmaceutically acceptable salt thereof, a hydrate or solvate thereof, or a mixture thereof for the preparation of an anti-inflammatory agent; povidone; and hydroxypropylbetadex.
- the "individual” may refer to any animal, including humans, that is likely to cause inflammation.
- the "administration" means introducing the eye drop composition of the present invention to an individual by any suitable method, and the administration route of the present invention may be topical administration to the eye due to the nature of the composition as an eye drop.
- the anti-inflammatory method of the present invention includes administering the eye drop composition of the present invention in a therapeutically effective amount.
- composition of the present invention maintains properties and content during storage and exhibits excellent stability by minimizing the generation of related substances, and thus can be usefully used as an eye drop for analgesic and/or anti-inflammatory purposes.
- a composition was prepared according to the components and contents of Table 1 below. Specifically, in Example 1, 2 g of povidone K30 was added and dissolved in 80 mL of sterile purified water, and then 0.5 g of anhydrous sodium monohydrogen phosphate was added and completely dissolved. After adding 1 g of hydroxypropyl betadex and stirring for a certain period of time, it was confirmed that hydroxypropyl betadex was completely dissolved, 0.15 g of sodium bromfenac hydrate (1.5 hydrate) was added to dissolve, and hydrochloric acid was added in an appropriate amount. The total composition was 100 mL with sterile purified water, and the composition was prepared by aseptic filtration (0.2 ⁇ m, membrane filter). The pH of the prepared solution is about 7.8. Comparative Examples 1 to 3 were prepared in the same manner as in Example 1, except for adding povidone and/or HP- ⁇ -CD.
- the prepared composition was stored under severe conditions (55° C., 70% RH) for 5 weeks, and then the properties were observed with the naked eye.
- the composition of Comparative Examples 1 and 2 changed to orange in appearance, and in Comparative Example 3, crystalline precipitation occurred, making it difficult to prepare and use as an eye drop composition, whereas the composition of Example 1 had a transparent yellow appearance. There was no change, and no precipitation occurred. Through this, it can be seen that the ophthalmic composition of the present invention has excellent stability.
- Examples 1 and Comparative Examples 1 to 3 compositions were prepared. After storing the prepared composition under severe conditions (55 °C, 70% RH) for 5 weeks, 7-(4-bromobenzoyl)indolin-2-one (7-(4- bromobenzoyl)indoline-2-one, related substances A) and 2-amino-3-(4-bromobenzoyl)phenyloxoacetic acid (2-amino-3(4-bromobenzoyl)phenyloxoacetic acid, related substances B) It was measured using a liquid chromatography method and the content (%) compared to the bromfenac content was calculated. It is preferable that the amount of related substance A is 0.2% or less and that of related substance B is 1% or less relative to the content of bromfenac.
- the compositions of Comparative Examples 1 to 3 showed a high content of related substances A or B, whereas the composition of Example 1 had low contents of related substances A and B (Table 2).
- the ophthalmic composition of the present invention has excellent stability.
- a composition was prepared according to the components and contents of Table 3 below. Specifically, in Example 2, 4 g of povidone K30 was added and dissolved in 80 mL of sterile purified water, and then 1 g of anhydrous sodium monohydrogen phosphate was added and completely dissolved. After adding 2 g of hydroxypropyl betadex and stirring for a certain period of time to confirm that hydroxypropyl betadex is completely dissolved, 0.3 g of sodium bromfenac hydrate (1.5 hydrate) was added to dissolve, and hydrochloric acid was added in an appropriate amount. The total composition was 100 mL with sterile purified water, and the composition was prepared by aseptic filtration (0.2 ⁇ m, membrane filter). The pH of the prepared solution is about 7.8. Comparative Examples 4 to 6 were prepared in the same manner as in Example 2 except for adding povidone and/or HP- ⁇ -CD.
- a composition was prepared according to the components and contents of Table 4 below. Specifically, in Example 3, 0.5 g of povidone K30 was added and dissolved in 80 mL of sterile purified water, and then 0.5 g of anhydrous sodium monohydrogen phosphate was added and completely dissolved. After adding 5 g of hydroxypropyl betadex and stirring for a certain period of time to confirm that hydroxypropyl betadex is completely dissolved, 0.05 g of sodium bromfenac hydrate (1.5 hydrate) was added to dissolve, and hydrochloric acid was added in an appropriate amount. The total composition was 100 mL with sterile purified water, and the composition was prepared by aseptic filtration (0.2 ⁇ m, membrane filter). The pH of the prepared solution is about 7.8. Examples 4 and 5 were prepared in the same manner as in Example 3 with the content of the composition components as shown in Table 4.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (11)
- 브롬페낙(bromfenac), 이의 약학적으로 허용가능한 염, 이들의 수화물 또는 용매화물, 또는 이들의 혼합물; 포비돈(povidone); 및 히드록시프로필베타덱스(Hydroxypropylbetadex)를 포함하는 점안 조성물.
- 제1항에 있어서, 상기 브롬페낙, 이의 약학적으로 허용가능한 염, 이들의 수화물 또는 용매화물, 또는 이들의 혼합물은 브롬페낙나트륨수화물인 것인, 점안 조성물.
- 제1항에 있어서, 상기 브롬페낙(bromfenac), 이의 약학적으로 허용가능한 염, 이들의 수화물 또는 용매화물, 또는 이들의 혼합물은 총 점안 조성물 기준 약 0.01 w/v% 내지 약 0.5 w/v%의 함량으로 포함되는 것인, 점안 조성물.
- 제1항에 있어서, 상기 포비돈은 총 점안 조성물 기준 약 0.1 w/v% 내지 약 10.0 w/v%의 함량으로 포함되는 것인, 점안 조성물.
- 제1항에 있어서, 상기 히드록시프로필베타덱스는 총 점안 조성물 기준 약 0.05 w/v% 내지 약 20.0 w/v%의 함량으로 포함되는 것인, 점안 조성물.
- 제1항에 있어서, 상기 조성물은 pH 조절제, 완충제, 등장화제, 점도조절제, 용해보조제, 안정화제 및 보존제 중에서 선택된 1종 이상의 첨가제를 추가로 포함하는 것인, 점안 조성물.
- 제1항에 있어서, 상기 조성물의 pH는 약 5 내지 약 9인 것인, 점안 조성물.
- 제1항에 있어서, 상기 조성물은 항염증용인 것인, 점안 조성물.
- 제1항 내지 제7항 중 어느 한 항에 따른 점안 조성물을 개체에 투여하는 단계를 포함하는 항염 방법.
- 제1항 내지 제7항 중 어느 한 항에 따른 점안 조성물의 항염 용도.
- 항염증용 약제의 제조를 위한 제1항 내지 제7항 중 어느 한 항에 따른 점안 조성물의 용도.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22742869.5A EP4282403A2 (en) | 2021-01-21 | 2022-01-21 | Ophthalmic composition |
CN202280010772.6A CN116801865A (zh) | 2021-01-21 | 2022-01-21 | 眼用组合物 |
JP2023544198A JP2024504980A (ja) | 2021-01-21 | 2022-01-21 | 点眼組成物 |
CA3203779A CA3203779A1 (en) | 2021-01-21 | 2022-01-21 | Ophthalmic composition |
US18/271,287 US20240082188A1 (en) | 2021-01-21 | 2022-01-21 | Ophthalmic composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210008925 | 2021-01-21 | ||
KR10-2021-0008925 | 2021-01-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022158893A2 true WO2022158893A2 (ko) | 2022-07-28 |
WO2022158893A3 WO2022158893A3 (ko) | 2023-04-06 |
Family
ID=82548864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/001095 WO2022158893A2 (ko) | 2021-01-21 | 2022-01-21 | 점안 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240082188A1 (ko) |
EP (1) | EP4282403A2 (ko) |
JP (1) | JP2024504980A (ko) |
KR (2) | KR102489633B1 (ko) |
CN (1) | CN116801865A (ko) |
CA (1) | CA3203779A1 (ko) |
WO (1) | WO2022158893A2 (ko) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4910225A (en) | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4910225B1 (ko) | 1969-08-02 | 1974-03-08 | ||
JP4910225B2 (ja) | 1999-11-09 | 2012-04-04 | 東洋紡績株式会社 | 透明導電性フィルム、及びこれを用いたエレクトロルミネッセンスパネル及びタッチパネル |
AU2010339993A1 (en) * | 2009-12-15 | 2012-07-26 | Foresight Biotherapeutics, Inc. | Non-irritating ophthalmic povidone-iodine compositions |
WO2012009696A2 (en) * | 2010-07-15 | 2012-01-19 | Corinthian Ophthalmic, Inc. | Ophthalmic drug delivery |
PE20141070A1 (es) * | 2011-05-12 | 2014-09-14 | Foresigth Biotherapeutics Inc | Composiciones estables de povidona yodada con antiinflamatorios esteroideos o no esteroideos |
ES2903383T3 (es) * | 2016-11-29 | 2022-04-01 | Oculis SA | Preparación de complejos sólidos de ciclodextrina para la administración de un principio farmacéutico activo oftálmico |
-
2022
- 2022-01-21 US US18/271,287 patent/US20240082188A1/en active Pending
- 2022-01-21 EP EP22742869.5A patent/EP4282403A2/en active Pending
- 2022-01-21 KR KR1020220008917A patent/KR102489633B1/ko active IP Right Grant
- 2022-01-21 JP JP2023544198A patent/JP2024504980A/ja active Pending
- 2022-01-21 CA CA3203779A patent/CA3203779A1/en active Pending
- 2022-01-21 CN CN202280010772.6A patent/CN116801865A/zh active Pending
- 2022-01-21 WO PCT/KR2022/001095 patent/WO2022158893A2/ko active Application Filing
-
2023
- 2023-01-12 KR KR1020230004956A patent/KR20230014809A/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4910225A (en) | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
Also Published As
Publication number | Publication date |
---|---|
JP2024504980A (ja) | 2024-02-02 |
CN116801865A (zh) | 2023-09-22 |
US20240082188A1 (en) | 2024-03-14 |
CA3203779A1 (en) | 2022-07-28 |
KR20230014809A (ko) | 2023-01-30 |
KR102489633B1 (ko) | 2023-01-17 |
WO2022158893A3 (ko) | 2023-04-06 |
KR20220106077A (ko) | 2022-07-28 |
EP4282403A2 (en) | 2023-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6333045B1 (en) | Aqueous liquid pharmaceutical composition comprised of gatifloxacin | |
ES2389566T3 (es) | Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva | |
US7829544B2 (en) | Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac | |
JPWO2008044734A1 (ja) | ガチフロキサシン含有水性液剤 | |
WO2022158893A2 (ko) | 점안 조성물 | |
WO2020004784A1 (ko) | 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법 | |
KR20010022113A (ko) | 주성분으로서 벤조피란 유도체를 함유하는 수성 액체 제약조성물 | |
WO2019059479A1 (ko) | 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법 | |
WO2021261930A1 (ko) | 디쿠아포솔을 포함하는 점안 조성물 | |
EP3355929A1 (en) | Novel ophthalmic composition comprising rebamipide and method for preparing the same | |
WO2012074237A2 (ko) | 도르졸라미드, 티몰롤 및 브리모니딘을 포함하는 안과용 액제 조성물 | |
WO2022108334A1 (ko) | 세티리진 및 토코페솔란을 포함하는 안과용 조성물 | |
WO2019171260A1 (en) | Pharmaceutical composition of lifitegrast | |
WO2018111021A1 (ko) | 설파살라진 및 히알루론산을 함유하는 안약 조성물 | |
WO2018236158A1 (ko) | 녹내장 치료용 점안 조성물 | |
WO2024071979A1 (ko) | 브리모니딘을 포함하는 안과용 조성물 | |
WO2021261931A1 (ko) | 디쿠아포솔을 포함하는 점안 조성물 | |
JP4754149B2 (ja) | 水性液剤 | |
WO2022092868A1 (ko) | 안과용 조성물 | |
WO2019177320A1 (ko) | 우수한 안정성을 갖는 폴마콕시브 함유 주사액 조성물 및 이의 제조방법 | |
JP2005247804A (ja) | 点眼剤 | |
JPS60115520A (ja) | 眼性高血圧症の治療のための末梢的に選択的なドーパミン拮抗物質 | |
WO2014010924A1 (en) | Pharmaceutical composition for topical administration comprising vancomycin or its salt and dexamethasone phosphate or its salt | |
WO2010008135A1 (en) | Oral soft capsule of aceclofenac having improved stability | |
WO2023014117A1 (ko) | 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22742869 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 3203779 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18271287 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280010772.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023544198 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022742869 Country of ref document: EP Effective date: 20230821 |